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ABSTRACT: Intrahepatic cholestasis of pregnancy (ICP) causes increased transfer of maternal bile acids to the fetus
and an increased incidence of sudden fetal death. Treatment includes ursodeoxycholic acid (UDCA), but it is not
clear if UDCAprotects the fetus. This study explores the placental transport of the bile acid taurocholate (TC) by the
organic anion–transporting polypeptide, (OATP)4A1, its effects on the placental proteome and vascular function,
and how these are modified by UDCA. Various methodological approaches including placental villous fragments
and Xenopus laevis oocytes were used to investigate UDCA transport. Placental perfusions and myography in-
vestigated the effect of TC on vasculature. The effects of acute TC exposure on placental tissue were investigated
using quantitative proteomics. UDCA inhibited OATP4A1 activity in placental villous fragments and oocytes. TC
induced vasoconstriction in placental and rat vasculature, whichwas attenuated byUDCA.Quantitative proteomic
analysis of villous fragments showeddirect effects of TConmultipleplacental pathways, including oxidative stress
and autophagy. The effects of TC on the placental proteome and vasculature demonstrate howbile acidsmay cause
fetaldistress in ICP.UDCAinhibitionofOATP4A1 suggests itwill protect themother and fetus against the vascular
effects ofTCby inhibiting its cellularuptake.UDCAmayprotect the fetus in ICPby inhibitingOATP4A1-mediated
bile acid transfer andTC-inducedplacental vasoconstriction.Understanding thephysiologicmechanismsofUDCA
may allowbetter therapeutic interventions to be designed specifically for the fetus in the future.—Lofthouse, E.M.,
Torrens, C., Manousopoulou, A., Nahar, M., Cleal, J. K., O’Kelly, I. M., Sengers, B. G., Garbis, S. D., Lewis, R. M.
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Intrahepatic cholestasis of pregnancy (ICP) is a disease
characterized by elevated maternal and fetal plasma
bile acids, whichmay have severe short-term and long-
term consequences for the fetus (1, 2). Although
maternal prognosis is good, ICP poses significant
risks, including fetal distress, preterm delivery, and, in
severe cases, spontaneous fetal death (3).
The 2 classes of primary bile acids are cholic acid and
chenodeoxycholic acid, which are synthesized from
cholesterol in the liver and converted to secondary bile acids
(taurocholic acid, glychocholic acid, glycochenodeoxycholic
acid, and taurochenodeoxycholic acid) by conjugation or
enzymatic modification, which occurs in the liver, or by in-
testinal bacteria. Within these classes of primary and sec-
ondarybileacids,multiplesubtypesarepresent, representing
different chemicalmodifications (4, 5). Bile acids are secreted
into theduodenumand,after facilitating lipidabsorption,are
reabsorbed from the terminal ilium and recycled to the liver.
From early on in gestation, the fetal liver synthesizes
bile acids, which are removed from the fetal circulation
by placental transfer to the maternal circulation. How-
ever, in ICP, high maternal levels of bile acids result in
reversed transfer and may also competitively inhibit
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physiologic transfer of fetal bile acids to the mother (5).
Consequently, these 2 factors result in a significant ac-
cumulation of maternal bile acids in the fetal circula-
tion. It is not clear how increased bile acid concentrations
have adverse effects on the fetus, but there is evidence
that they increase smooth muscle contractility in the
placental vasculature and reduce synchronicity in fetal
cardiomyocytes (6–8). Elevated bile acid concentrations
could adversely affect placental function, leading to sec-
ondary effects on the fetus. For example, changes in
placental membrane transporter expression have been
reported,with theorganic anion–transportingpolypeptide
(OATP)4A1 and OATP2B1 mRNAs being up-regulated
and down-regulated, respectively, in ICP placentas (9, 10),
which may affect placental function.
To cross the placenta, bile acids need to be transported
across both the maternal-facing microvillous membrane
and the fetal-facing basal membrane of the placental syn-
cytiotrophoblast aswell as the fetal capillary endothelium.
It is unclear whether the placentametabolizes maternal or
fetal bile acids. A deeper understanding of how bile acids
are transported across the polarized syncytiotrophoblast
can provide insight as to how their transfer to the fetus can
be inhibited.
A variety of transporters are expressed in the placenta
that could facilitate bile acid transfer in both the maternal
and fetal directions. These include the OATPs such as
OATP4A1, which has been reported to be up-regulated in
cholestasis placentas (11),OATP2B1, and the breast cancer
resistanceprotein effluxpump(12). In the liver, thebile salt
export pump and the sodium taurocholate (TC) cotrans-
porting polypeptide SLC10A1 are the major bile acid
transporters, but their expression in the placenta is negli-
gible (13).
The treatment of ICP currently involves administering
a naturally occurring bile acid, ursodeoxycholic acid
(UDCA), to alleviate maternal symptoms by altering the
composition of the bile acid pool (14). The mechanisms
behind this mode of action are unclear, although it is re-
ported that UDCA reduces apoptosis, villitis of unknown
etiology, and bile acid–induced oxidative stress and in-
flammatory effects on placental trophoblasts (14–16).
UDCAis reported tobe safe for the fetus, but it isunknown
what effects UDCA has on placental function (17, 18).
Although UDCA is prescribed in clinical practice, there is
not a consensus as to whether UDCA is beneficial (19).
There is a need for a broader physiological understanding
of how UDCAmay affect the placenta because this could
changeplacental functionandalter fetaldevelopment (19).
The primary purpose of this study was to investigate
the transport of the bile acid TC across the human pla-
centa and the effects of UDCA on bile acid transport and
placental function. Because OATP4A1 is reportedly up-
regulated in ICP, a combination of placental villous frag-
ments and OATP4A1-expressing Xenopus laevis oocytes
were used to investigate the uptake of TC and UDCA
across the microvillous membrane of the placental syn-
cytiotrophoblast, whereas human placental perfusions
andmyographywere used to investigate the mechanisms
underlying bile acid–mediated vasoconstriction.
MATERIALS AND METHODS
Study approval
Placentas were collected with written informed consent from
womendeliveringat thePrincessAnneHospital in Southampton
with approval from theSouthamptonandSouthwestHampshire
Local Ethics Committee (11/SC/0529).
All animal procedureswere performed in accordancewith the
regulations of the British Home Office Animals (Scientific Proce-
dures) Act 1986 and approved by the local Ethical Review Com-
mittee. Formyography studies,maleWistar rats (300–400 g) from
Charles River Laboratories (Wilmington, MA, USA) were used.
cRNA synthesis for microinjection into oocytes
The plasmid containing the cDNA of human OATP4A1
[Solute carrier organic anion transporter family member 4A1
(SLCO4A1)] was obtained fromOrigene (Rockville, MD, USA)
and was linearized using the Streptomyces achromogenes SacI
restriction enzyme (Promega; Madison, WI, USA). Because the
plasmid contained 2 bacteriophage T7 (T7) promoter sites, PCR
was used to amplify the region containing only the first T7
promoter and the SLCO4A1gene before purification to prevent
synthesis of cRNA from the noncoding T7 site (forwardprimer:
59-GCACCAAAATCAACGGGACT-39, reverse primer: 59-
CAACGGCACTGTTCTGTCAT-39). cRNA was synthesized
from the coding T7 promoter using the Ambion mMachine
mMessage Kit (Thermo Fisher Scientific, Waltham, MA, USA)
according to the manufacturer’s instructions.
Xenopus oocyte transstimulation studies
Xenopus laevis oocytes were used as an expression system for the
characterization of OATP4A1.
Xenopus laevis oocytes were obtained from the European
Xenopus Resource Centre (Portsmouth, United Kingdom). Oo-
cytes were treated with collagenase (2 mg/ml) in buffer OR2
(2.5 mKCl, 82.5 mMNaCl, 1 mMCaCl2, 1 mMNa2HPO4, 1 mM
MgCl2, and 5 mMHEPES) for 1 h at room temperature. Oocytes
were then incubated in ND91 buffer (2 mM KCl, 91 mM NaCl,
1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, 1% penicillin-
streptomycin, and 0.1% gentamycin sulfate) overnight at 18°C.
Stage V oocytes were injected with 20 ng of OATP4A1 cRNA
dissolved in 38 nl of water. The water-injected control oocytes
were injected with an equivalent volume of water.
3H-estrone sulfate uptake studies
OATP4A1 transports a wide variety of steroid hormones and
drugs in addition to bile acids. Previously, X. laevis oocytes were
found to endogenously express a carrier system thatmediatedTC
efflux (20).Asa result, the 3H-estronesulfate (3H-ES)wasusedasa
model substrate for inhibiting OATP4A1 transporter activity.
Two to three days after injection of OATP4A1 cRNA, individual
oocytes were transferred to single wells of a 96-well plate and
incubatedwith 3H-ES (11mM) inND91buffer for 2.5–30minwith
or without the presence of 2.5 mM glutamate or ES to inhibit
uptake. Uptakewas then stopped bywashing the oocytes 3 times
in cold ND91 buffer. Each oocyte was homogenized in 5% SDS,
and levels of tracerwere analyzed by liquid scintillation counting.
3H-ES efflux studies
To determine whether OATP4A1 mediates UDCA transport,
individual OATP4A1 cRNA and water-injected oocytes were
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incubated with 3H-ES (6 nM) for 1 h in sodium-free ND91. Each
oocyte was washed 3 times in warm sodium-free ND91 before
100 ml of buffer alone, 500 mM ES, 500 mMUDCA, or 500 mM
glycine was added for 5 min to stimulate efflux of 3H-ES.
Efflux was stopped after 5 min, and the efflux buffer of 5
individual oocytes was combined (500 ml total) and analyzed
by liquid scintillation counting (5 oocytes/condition, 3 rep-
licates). Each independent experiment used oocytes from a
different frog and was conducted on a different week.
Placental villous fragments
Radiolabeled uptake time-course experiments
Villous fragments (10 mg) were dissected from human term
placentas and cultured for 0, 1, 2.5, 5, 7.5, 10, 30, or 60 min in
Tyrode’s buffer [135 mM NaCl, 5 mM KCl, 1.8 mM CaCl2,
1 mMMgCl26.H2O, 10 mMHEPES, and 5.6 mM glucose (pH
7.4)] containing 5 nM 3H-ES (9.25 MBq, NET203250UC;
PerkinElmer,Waltham,MA, USA) (n = 3 placentas, duplicate
conditions, 3 fragments per replicate) or 16 nM 3H-taurocholic
acid (3H-TC) (9.25 MBq, NET322250UC; PerkinElmer). Uptake
was stopped by washing the fragments in cold Tyrode’s buffer
before homogenizing the fragments in NaOH (50 mM). Uptake
of 3H-ES and 3H-TC was determined by liquid scintillation
counting (PerkinElmer).
Uptake inhibition experiments
Villous fragments (10 mg) were dissected from human term
placentas and cultured for 2.5min or 1min (as determined by
time-course experiments) in Tyrode’s buffer containing
26 nM 3H-ES or 106 nM 3H-TC, respectively (n = 5 placentas),
with or without 100 mM–1 mM ES (n = 5 placentas), glycine
(n = 5 placentas), TC (n = 5 placentas), or 10mM–1mMUDCA
(n . 3 placentas). To ensure complete inhibition of OATP4A1-
mediated transport, the concentrations of these substrateswere
used above physiological levels. Conditions were done
in triplicate with 3 fragments per replicate. Uptake of 3H-ES
or 3H-TC was stopped by washing the fragments in cold
Tyrode’s buffer before homogenizing the fragments in
NaOH (50 mM). Uptake of the tracer was determined by
liquid scintillation counting (PerkinElmer).
Proteomics experiments
Villous fragments (10 mg) were dissected from human term
placentas and cultured for 8 h in Tyrode’s buffer alone or
100 mM TC in Tyrode’s buffer (n = 3 placentas, 3 replicate
conditions, 3 fragments/replicate).
Vascular function
Placentas were perfused using the methodology of Schneider et al.
(21), asadaptedinour laboratory(22).Placentaswereperfusedwith
Earle’s Bicarbonate Buffer (5 mM glucose, 1.8 mM CaCl2, 0.4 mM
MgSO4, 116.4 mM NaCl, 5.4 mM KCl, 26.2 mM NaHCO3, and
0.9 mM NaH2PO4) and gassed with 5% CO2 and 95% O2 via the
fetal catheter going into the chorionic plate fetal artery at 6ml/min
and via 5 maternal catheters at 14 ml/min using a roller pump. At
20-min intervals,boliof1mMTC(estimatedmaximalconcentration
in tissue after dilution 380 mM) and 20 nM angiotensin were per-
fused into the fetal circulation (n = 8). Throughout the experiment,
fetal and maternal placental circulation pressures were recorded
using Chart v.4.2 (ADInstruments, Oxford, United Kingdom).
Myography
Human placental arteries
Arteries from the human term placental chorionic plate were
mountedonawiremyograph(DanishMyoTechnology,Aarhus,
Denmark) in physiologic salt solution (PSS) of the following
composition: NaCl, 119; KCl, 4.7; CaCl2, 2.5; MgSO4, 1.17;
NaHCO3, 25;KH2PO4, 1.18;EDTA,0.026; andD-glucose, 5.5mM.
Segments were bathed in PSS, heated to 37°C, and continuously
gassed with 95% O2 and 5% CO2. Smooth muscle integrity was
assessed by a single wash with 125 mM PSS solution with an
equimolar substitution of KCl for NaCl. Following equilibration,
cumulative concentration response curves (CRCs) were con-
structed to the bile acid TC (1 nM–100mM, n = 5 placentas) in the
absence or presence of the organic anion transporter (OAT) in-
hibitor ES (100mM, n= 3 placentas) and theCa2+ channel blocker
nifedipine (1mM,n=2placentas). Responses to the thromboxane
mimetic U46619 (1 mM, n = 3 placentas) were also performed.
Rat thoracic aorta
Male Wistar rats (350–450 g; Charles River Laboratories) were
humanely killed by CO2 inhalation and cervical dislocation. The
thoracic aorta was dissected and cut into 2-mm segments and
mounted on amyograph as previously described. Thoracic aorta
segments were placed under a resting tension of 1 g, and smooth
muscle integritywas assessed by a singlewashwith 125mMPSS
solution with an equimolar substitution of KCl for NaCl. Fol-
lowing equilibration, cumulative CRCs were constructed to the
a1-adrenoceptor agonist phenylephrine (1 nM–100 mM, n = 13).
Cumulative CRCs were then constructed to the bile acid TC
(1nM–100mM,n=13)aloneor in thepresenceofnifedipine (1mM,
n= 3) and theOAT inhibitorsUDCA (100mM, n= 5), ES (100mM,
n = 4), and bromosulphothalein (100 mM, n = 7).
Quantitative proteomics sample processing
Placental villous fragments were snap frozen at 280°C. These
were dissolved in 0.5 M triethylammonium bicarbonate and
0.05% SDS and subjected to pulsed probe sonication (Misonix,
Farmingdale, NY, USA). Lysates were centrifuged (16,000 g,
10min, 4°C)andsupernatantsweremeasured forprotein content
using infrared spectroscopy (MilliporeSigma, Burlington, MA,
USA). Lysates were then reduced, alkylated, and subjected to
trypsin proteolysis. Peptides were labeled using the eight-plex
iTraq reagent kit (MilliporeSigma; 113 = control 1, 114 = TC 1,
115 = control 2, 116 = TC 2, 117 = control 3, 118 = TC 3, 119 =
control 4, and 121 = TC 4) and analyzed using 2-dimensional
liquid chromatography (offline alkaline C4 reverse phase and
online acidic C18 reverse phase) and tandem mass spectrometry
as previously reported by the authors (23, 24).
Database searching
Unprocessed raw files were submitted to Proteome Discov-
erer 1.4 (Thermo Fisher Scientific) for target decoy searching
against the UniProt Knowledgebase Homo sapiens database
(https://www.uniprot.org/proteomes/UP000005640) composed
of 20,159 entries (release date, January 2015), allowing for up
to 2 missed cleavages, a precursor mass tolerance of 10 ppm, a
minimum peptide length of 6, and a maximum of 2 variable (1
equal) modifications of 8-plex iTraq (Y), oxidation (M), dea-
midation (N, Q), or phosphorylation (S, T, and Y). Methylthio
(C) and iTraq (K, Y, and N terminus) were set as fixed modifi-
cations. False discovery rate at the peptide level was set at
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,0.05. Percent coisolation excluding peptides from quantita-
tion was set at 50. Reporter-ion ratios from unique peptides
only were taken into consideration for the quantitation of the
respective protein. A 1-sample Student’s t test using the nor-
malized iTraq ratios of each TC-treated placenta compared
with its respective control was performed. Significance was
set at P # 0.05. In adherence to the Paris Publication Guide-
lines for the analysis and documentation of peptide and
protein identifications (https://doi.org/10.1074/mcp.T400006-
MCP200) only proteins identified with at least 2 unique pep-
tides were further subjected to bioinformatics. All mass
spectrometrydata have beendeposited to theProteomeXchange
Consortium via the Proteomics IdentificationsArchivewith the
data set identifier PXD009825.
Bioinformatics analysis
The Database for Annotation, Visualization and Integrated Dis-
covery (DAVID; https://david.ncifcrf.gov/) was applied to differ-
entially expressed proteins in order to identify overrepresented
gene ontology (GO) terms. A Fisher exact–corrected value of P#
0.05 was considered significant.
Statistics
3H-ES and 3H-TC uptake in OATP4A1 oocytes and placental
villous fragments was analyzed by a 1-way ANOVA with a
Dunnett’s post hoc test, in which 3H-ES or 3H-TC uptake in the
presence of OATP4A1 substrates was compared with the tracer
alone.
3H-ES efflux in OATP4A1 oocytes was analyzed by a 1-way
ANOVA with a Dunnett’s post hoc test, in which 3H-ES efflux
stimulated by OATP4A1 substrates was compared with 3H-ES
efflux in response to buffer alone. Significance was assumed at a
value of P , 0.05, and oocyte data were adjusted for water-
injected responses and presented as means6 SEM.
Placental perfusion peak force datawere adjusted for baseline
pressure and analyzed using an unpaired Student’s t test in
which data were compared with a hypothetical value of 0. Sig-
nificance was assumed at a value of P, 0.05. Data are presented
as means6 SEM.
Responses in rat aortas and chorionic plate vessels were
measured as the percentage of maximum response in the pres-
ence or absence of inhibitor. Data are presented as means6 SEM,
and significance was assumed at a value of P, 0.05.
RESULTS
Human tissue data
Placentas used in this study were obtained from normal-
termdeliveries, ofwhich 70%were caesareans andwithan
average parity of 1.5.
OATP4A1 activity is inhibited by UDCA
Placental villous fragment uptake experiments were car-
ried out to investigateOATP-mediated ES andTCuptake.
Figure 1. The uptake of OATP
substrates, ES and TC, are
inhibited by UDCA in placental
villous fragments. A) 3H-ES up-
take by villous fragments was
shown to be linear up to 5 min
(n = 2 placentas). B) 3H-TC
uptake by villous fragments was
shown to be linear up to 2.5 min
(n = 3 placentas). C) 3H-ES
uptake was inhibited by 1 mM
ES (***P , 0.001, n = 5), 1 mM
TC (***P , 0.001, n = 5), and
1 mM UDCA (**P, 0.01, n = 5)
but not by the negative control
glycine (n = 5). D) 3H-TC
uptake was inhibited by
100 mM UDCA (***P , 0.01,
n = 5), 100 mM TC (**P , 0.01,
n = 5), and 100 mM ES (***P ,
0.01, n = 5), but not by the
negative control glycine (n = 5).
Data are presented as means
and SEM and were analyzed by a
1-way ANOVA with Dunnett’s
post hoc (compared with 3H-ES
and 3H-TC alone).
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In placental villous fragments, uptake of the OATP4A1
substrate 3H-ESwas linear up to 10min (n= 2 placentas,
Fig. 1A), whereas uptake of 3H-TCwas linear up to 2 min
(n = 3 placentas, Fig. 1B). Subsequent uptake experiments
in villous fragments were carried out at the 2.5 min time
point for 3H-ES and 1 min for 3H-TC. 3H-ES uptake was
inhibitedby1mMES (P,0.001,n=5placentas), 1mMTC
(P, 0.001, n = 5 placentas), and 1 mMUDCA (P, 0.006,
n = 5 placentas; Fig. 1C). 3H-TC uptake was inhibited by
100mMTC(P,0.001,n=5placentas),100mMES(P,0.001,
n = 5 placentas), and 100 mMUDCA (P, 0.001, n = 5 pla-
centas; Fig. 1D). 3H-TC uptake was also inhibited by
200mMUDCA (P, 0.05, n= 3placentas) but not by 10 or
50 mMUDCA (Fig. 2).
Xenopus oocytes were injected with water alone or
SLCO4A1 cRNA in order to express the OATP4A1 trans-
porter so transport function could be investigated. In
Xenopus oocytes expressing the OATP4A1 protein, 3H-ES
uptake was linear for 10 min and was inhibited by cold
2.5mMES (Fig. 3A). Subsequent uptake experimentswere
performed at 10 min. 3H-ES uptake (under sodium-free
conditions) in oocytes injectedwithOATP4A1 cDNAwas
inhibited by 500mMES, TC, andUDCA (P, 0.05) but not
by the negative control glycine (Fig. 3B).
UDCA is not transported by OATP4A1
In OATP4A1-expressing Xenopus oocytes, 500 mM of
OATP4A1 substrate ES (P = 0.02, n = 3 ovaries, triplicate
conditions) and 500 mM TC (P = 0.002, n = 3 ovaries)
transstimulated efflux of 3H-ES (Fig. 3C). Efflux was not
stimulated by buffer alone, 500mMUDCA (n = 3 ovaries),
or the negative control glycine (n = 3 ovaries).
Figure 3. UDCA inhibits OATP4A1 but does not cause
transstimulation, suggesting it is not transported. A) 3H-ES
uptake into oocytes by OATP4A1 was shown to be linear up to
10 min, and this was inhibited by cold 2.5 mM ES (n = 5
ovaries, 5 oocytes per condition). B) 3H-ES uptake (under
sodium-free conditions) in OATP4A1-injected oocytes was
inhibited by 500 mM ES, TC, and UDCA (*P , 0.05, n = 5
ovaries, 5 oocytes/condition), but not by negative control
glycine. Data are presented as means and SEM and are analyzed
by a 1-way ANOVA with Dunnett’s post hoc (compared with 3H-
ES alone). C) 3H-ES efﬂux in OATP4A1-injected oocytes is
transstimulated by ES (*P , 0.05, n = 3) and TC (**P , 0.01),
but not by UDCA or negative control glycine. This suggests
that UDCA is not a substrate of OATP4A1. Data are adjusted
for background water-injected responses and presented as
means and SEM. Data were analyzed by a 1-way ANOVA with
Dunnett’s post hoc (compared with buffer alone); n . 3
individual ovaries, 5 oocytes per condition for uptake, 15
oocytes/condition for efﬂux.
Figure 2. UDCA inhibits TC uptake in placental villous
fragments in a dose-dependent manner. Compared with 3H-
TC alone, 100–200 mM UDCA inhibited TC uptake (*P , 0.05,
n = 3 placentas, triplicate conditions, 3 fragments/replicate).
Data are presented as means and SEM and were analyzed by a
1-way ANOVA with Dunnett’s post hoc (compared with 3H-TC
alone).
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TC induces vasoconstriction in human
placental vasculature
Following an infusion of a 1-mM TC bolus into the fetal
circulation of an ex vivo–perfused human placental coty-
ledon (final maximal tissue concentration, 380 mM), pres-
sure in the fetoplacental circulation increased 71% from
baseline (P = 0.01, n = 4 placentas, Fig. 4A). A bolus of the
vasoconstrictor angiotensin II (20nM)was injected into the
fetoplacental circulation as a positive control and in-
creased fetoplacental pressure by 125% from baseline (P =
0.01, n = 4 placentas). Placentas that did not show vaso-
constriction in response to angiotensin II were removed
from the analysis.
Myography in human chorionic plate vessels
and in rat aorta
To better characterize vascular responsiveness to TC,
myography was performed on isolated vessels. In cho-
rionic plate arteries from human term placenta, TC (n = 5)
produced a modest constriction (Fig. 4B) that was signifi-
cantly less potent than the thromboxane mimetic U46619
(1mM, n= 3).Although thiswas amodest response, itwas
abolished by both the calcium channel blocker nifedipine
(1mM,n=2)andOATinhibitorES (100mM,n=3,P,0.01;
Fig. 4B).
Because responses to TC in human placental chorionic
plate arteries were modest, rat aorta was used to allow a
Figure 4. TC induces vasocon-
striction in human placental
vasculature. A) In placental
perfusions, infusion of a 1 mM
TC bolus into the fetal circula-
tion (**P , 0.01, n = 4 perfu-
sions) and subsequently 20 nM
angiotensin II (**P , 0.011, n =
4 perfusions) signiﬁcantly in-
creased fetoplacental pressure
from baseline. Data are pre-
sented as means and SEM and
were analyzed using an un-
paired Student’s t test in which
data were compared with a
hypothetical value of 0. B) In
chorionic plate arteries from
human term placenta, TC (n =
5) produced a modest constric-
tion that was signiﬁcantly less
potent than the thromboxane mimetic U46619 (1 mM) (n = 3, **P, 0.01). Although this was a modest response, it was abolished
by both nifedipine (1 mM, = 2) and ES (100 mM, n = 3, **P , 0.01).
Figure 5. TC-induced concen-
tration-dependent vasoconstric-
tion in rat aortas is inhibited by
OATP substrates, UDCA, and
the calcium channel blocker
nifedipine. A) Vasoconstriction
is induced by phenylephrine
and TC (n = 13). B) TC
responses were abolished in
the presence of 1 mM nifedi-
pine, a calcium channel blocker
(n = 3, ***P , 0.005). C) TC
constriction is abolished in
the presence of UDCA (n = 5,
**P , 0.01). D) TC constriction
is abolished in the presence of
OAT inhibitor BSP (n = 7,
***P , 0.005) and ES (n = 4,
***P , 0.005).
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fuller analysis of TC responsiveness. In rat aortas, TC (n =
13) produced a concentration-dependent vasoconstriction
(Fig. 5A) that was significantly less potent than phenyl-
ephrine (n= 13; Fig. 5A) andwas abolished in the presence
of nifedipine (1mM, n = 3,P = 0.001; Fig. 5B). Responses to
TC were also abolished in the presence of the OAT inhib-
itors bromosulphothalein (100 mM, n = 7, P = 0.0003), ES
(100 mM, n = 4, P = 0.005), and UDCA (100 mM, n = 5, P =
0.006; Fig. 5C, D).
Proteomics
The quantitative proteomic analysis of term placental vil-
lous fragments exposed for 8 h to TC (100 mM, n = 4 pla-
centas) compared with patient-matched controls profiled
7908 unique protein groups (peptide level FDR, P, 0.05).
Of these proteins, 615 were differentially expressed fol-
lowing 8 h exposure to TC compared with control (Stu-
dent’s t test, P , 0.05). GO analysis of the differentially
expressed proteins following 8 h exposure to TC vs.
controls showed significant enrichment for GO terms re-
lated to metabolism, cell death, oxidative stress, and
vesicle-mediated transport (DAVID, Fisher exact–
corrected value of P # 0.05; Fig. 6A). The differentially
expressed proteins that map to cellular response to oxi-
dative stress, cell death, and vesicle-mediated transport
are presented in heatmap format in Fig. 6B.
DISCUSSION
This study provides novel insight into TC uptake by the
human placenta aswell as its effects on vascular reactivity
and protein-level perturbation of biologic pathways and
networks. We show that UDCA is a competitive inhibitor
of OATP4A1-mediated TC uptake, and as such, UDCA
can inhibit the vascular effects of TC. The effects of TC on
the placenta and its interaction with UDCA are directly
relevant to our understanding of the effects of ICP and
improving treatment for this condition, which is associ-
ated with increased fetal death incidence.
Figure 6. A) GO analysis of the differentially expressed proteins following 8 h exposure of placental villous fragments to TC vs.
controls showed signiﬁcant enrichment for GO terms related to metabolism, cell death, oxidative stress, and vesicle-mediated
transport. The dotted line indicates a value of P = 0.05. B) Differentially expressed proteins that map to signiﬁcant pathways
(cellular response to oxidative stress, cell death, and vesicle-mediated transport) presented in heatmap format representing the
ratio of expression in treated vs. control samples for each placenta.
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Wedemonstrate for the first time that TC is a vasoactive
bile acid in the human placenta, capable of raising perfu-
sion pressure in isolated perfused placental cotyledons
and constricting isolated chorionic plate arteries. The effect
of TC appeared stronger in the perfused placentas com-
pared with the chorionic plate arteries. This may indicate
that the site of TC action lies deeper within the placenta or
that the increase in resistance observed in the perfused
placenta represents the sum of a smaller effect across the
placental vasculature. In either case, TC-induced vaso-
constriction at the level seen in the perfused placenta
would increasework required by the fetal heart in order to
maintain adequate placental perfusion. Because TC may
also affect fetal cardiomyocytes, these attributes may col-
lectively contribute to the overall increased rate of fetal
death seen in ICP (25, 26).
We subsequently characterized the mechanisms in-
volved in mediating TC-induced vasoconstriction in rat
aortas. These data show that TC-induced vasoconstriction
is mediated, in part, via muscarinic cholinergic receptors
and by OATP transporters. Because constriction was
inhibited by known OATP inhibitors and UDCA, this in-
dicates that TC is transported into the cell to induce its
systemic effect (Fig. 7).Within the cell,wehypothesize that
TC or a metabolite can induce calcium entry, leading to
constriction of the vascular smooth muscle.
UDCA is used as amaternal therapy in ICP, but little is
known about its transportmechanism across the placenta.
This study sought to determine whether UDCA is trans-
ported by OATP4A1, which is known to utilize the pla-
cental glutamate gradient to transport TC (11, 27). UDCA
was found to be an inhibitor of OATP4A1 but did not
transstimulate its activity, so it does not appear to be a
substrate, as has been suggested by previous studies (28).
Because OATP4A1 does not appear to transport UDCA,
this raises the possibility that an unknown transporter or
mechanism is implicated in the transfer of UDCA to the
fetus.
The fetal protective effects of UDCAmay be associated
with its inhibitionofOATP4A1,which in turnprevents the
uptake of bile acids into the placenta. Consequently,
apoptosis-related pathways against the fetoplacental vascu-
lature and on the fetus itself aremitigated (29). There is some
debate about the use of UDCA in ICP because the mecha-
nisms of action are unclear and benefits for the fetus are
unknown(19).This studysuggests that theadministrationof
Figure 7. A) In cholestasis, high maternal bile
acid concentrations lead to reversal of the
normal direction of bile acid transfer being
reversed. Placental OATP4A1 activity inhibition
via UDCA prevents toxic bile acid uptake across
the microvillous membrane of the placental
syncytiotrophoblast. B) We propose that vaso-
constriction of placental smooth muscle results
from altered calcium signaling induced by a
rise in intracellular calcium from M2 receptors
and L-type calcium channels.
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UDCA is likely to have direct and indirect benefits for fetal
health by maintaining placental health and preventing bile
acid transport, respectively.
The agnostic proteomic analysis provided novel
protein-level evidence that short-term exposure of pla-
cental villi to TC significantly affectedmultiple pathways.
These pathways included those related to metabolism,
oxidative stress, and autophagy, consistentwith previous
studies on ICP placentas (30). This study demonstrates
that these changes in the proteome are direct effects of TC
and not secondary to the effects of ICP on the mother.
Changes in metabolic, oxidative stress, and autophagy
pathways could alter placental function in ways that are
detrimental to the fetus, especiallywith chronic exposure.
Changes in the expression of proteins associated with
calcium physiology (e.g., the calcium-regulating binding
protein calreticulin) may be implicated in the vasoactive
effects observed, but specific studies on smooth muscle
would be required to determine this.
In cholestasis, stillborn fetuses and their placentas are
reportedly hypoxic with high levels of oxidative stress
associated with prolonged constriction of placental cho-
rionic veins (31). In the present study, oxidative stress
pathwayswerealso significantlyaltered in response tobile
acid exposure because ferredoxin 1, a protein involved in
bile acid metabolism and transferring electrons into the
cytochrome p450 system, was up-regulated. Vascular cell
adhesion protein 1, an inflammatory gene, was also one of
the most up-regulated proteins, whereas the TP53-
inducible glycolysis and apoptosis regulator, a gene that
regulates glucose breakdown and promotes DNA repair,
was one of themost down-regulated proteins, whichmay
affect nutrient transfer as a result (32).
This investigation providesmechanistic insight into the
transport of bile acids across theplacenta anddescribes the
vascular effects of bile acids as well as effects on placental
function, which may have implications for ICP. The
myography andperfusionwork in this studydemonstrate
that bile acids mediate vasoconstriction that may directly
impact fetal health. Previously, bile acids have been
demonstrated to cause a loss of synchronicity of contrac-
tion in rat fetal cardiomyocytes (26, 29). Moreover, con-
ditions such as absent or reversed end-diastolic flow and
hypoxiaareknownto cause fetaldistress andreduced fetal
growth and are similarly associatedwith vasoconstriction
and poor placental perfusion, as we report here (33, 34).
This study indicates that the vascular effects of TC re-
quire it to be transported into the cell. Future research into
limiting the effects of cholestasis on themother or the fetus
may focuson inhibiting theuptakeofbile acids into cells or
on understanding how bile acids have their effects within
the cell. The use of UDCA or a higher-affinity analog
would have promise because it would block bile acid
transfer byOATP4A1 but does not seem to be transported
by it, so it would not itself affect the intracellular milieu.
HowTChaseffectswithin the cell remainsunclear, butour
data indicate that it affects both calcium entry and protein
expression, and we suggest that it or a metabolite may be
activating intracellular signaling pathways.
In summary, this study demonstrates that in ICP,
UDCA may help protect the fetus by preventing the
transfer of maternal bile acids to the fetus and by attenu-
ating their vascular and other intracellular effects. This
study provides mechanistic insight into the use of UDCA
asa therapy in ICP, and thismayallow thedevelopmentof
more effective interventions.
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